Long-Term Outcomes of Childhood Acute Lymphocytic Leukemia Treated with Adapted Berlin-Frankfurt-Münster (BFM) Protocols: A Multicentric Analysis from a Developing Country.

Autor: Horn PRCB; Department of Hematology, Universidade Estadual do Rio de Janeiro, Rio de Janeiro 20559-900, Brazil.; Bone Marrow Transplantation Unit, Instituto Nacional de Cancer, Rio de Janeiro 20230-130, Brazil., Ribeiro-Carvalho MM; Department of Hematology, Universidade Estadual do Rio de Janeiro, Rio de Janeiro 20559-900, Brazil., Azevedo AMB; Pediatric Hematolgy Department, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-617, Brazil., Sousa AM; Pediatric Hematolgy Department, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-617, Brazil., Faria S; Department of Hematology, Universidade Estadual do Rio de Janeiro, Rio de Janeiro 20559-900, Brazil., Wiggers C; Department of Hematology, Universidade Estadual do Rio de Janeiro, Rio de Janeiro 20559-900, Brazil., Rouxinol S; Pediatric Hematology Department, Hospital Federal da Lagoa, Rio de Janeiro 22470-050, Brazil., Schramm MT; Hematology Department, Instituto Nacional de Cancer, Rio de Janeiro 20230-130, Brazil., Sanches BS; Pediatric Hematolgy Department, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-617, Brazil.; National Institute of Science and Technology in Childhood Cancer Biology and Pediatric Oncology, Universidade Federal do Rio Grande do Sul, Porto Alegre 90010-150, Brazil., Duarte NL; Pediatric Hematolgy Department, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-617, Brazil., Seixas TSF; Bone Marrow Transplantation Unit, Instituto Nacional de Cancer, Rio de Janeiro 20230-130, Brazil., Gomes BE; Bone Marrow Transplantation Unit, Instituto Nacional de Cancer, Rio de Janeiro 20230-130, Brazil., Oliveira E; Pediatric Hematolgy Department, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-617, Brazil., Arcuri LJ; Bone Marrow Transplantation Unit, Instituto Nacional de Cancer, Rio de Janeiro 20230-130, Brazil.; Hospital Israelita Albert Einstein, Academic Research Organization, São Paulo 01305-000, Brazil., Costa ESD; Pediatric Hematolgy Department, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-617, Brazil.; National Institute of Science and Technology in Childhood Cancer Biology and Pediatric Oncology, Universidade Federal do Rio Grande do Sul, Porto Alegre 90010-150, Brazil., Land MGP; Pediatric Hematolgy Department, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-617, Brazil.; National Institute of Science and Technology in Childhood Cancer Biology and Pediatric Oncology, Universidade Federal do Rio Grande do Sul, Porto Alegre 90010-150, Brazil., Souza MHFO; Department of Hematology, Universidade Estadual do Rio de Janeiro, Rio de Janeiro 20559-900, Brazil.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2024 Aug 21; Vol. 16 (16). Date of Electronic Publication: 2024 Aug 21.
DOI: 10.3390/cancers16162898
Abstrakt: Introduction: The objective of the current study was to determine the survival probabilities of children and adolescents with acute lymphocytic leukemia treated with adapted Berlin-Frankfurt-Münster (BFM) protocols and compare our results with the original BFM reports.
Methods: This retrospective study included 695 patients up to 19 years old treated with adapted BFM protocols between 1997 and 2018 in four hospitals in Rio de Janeiro. The 1997-2007 and 2008-2018 cohorts were analyzed separately.
Results: More than half of the patients were stratified into the high-risk BFM classification. Overall and event-free survivals were, in the 1997-2007 period, respectively, 88% and 80% (BFM standard risk group-SRG), 75% and 67% (intermediate risk group-IRG), and 48% and 33% (high-risk group-HRG). The corresponding numbers for the 2008-2018 period were 93% and 84% (SRG), 75% and 63% (IRG), and 64% and 57% (HRG). In the second period, both the OS (HR = 0.71, p = 0.011) and EFS (HR = 0.62, p < 0.001) were higher. Except for the intermediate-risk group, the latter results are comparable to the BFM.
Conclusion: The BFM protocol adaptations can be safely implemented in developing countries, accounting for local specificities.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje